Skip to main content
. 2022 Jun 16;26:180. doi: 10.1186/s13054-022-04043-8

Table 3.

Baseline characteristics of the intracerebral and/or intraventricular subpopulation after propensity score-overlap weighting

Variable Andexanet alfa
n = 47
4F-PCC
n = 37
Demographics
Age (years), mean ± SD 77 ± 9 77 ± 10
Male, % 51.4 51.4
Body mass index (kg/m2), mean ± SD 28 ± 9 28 ± 6
Creatinine clearance (mL/min), mean ± SD 73 ± 32 73 ± 48
Systolic blood pressure > 160 mm Hg, %a 15.3 15.3
GCS score, %b 14 ± 1 13 ± 2
Anticoagulant indication and medical history, %
Anticoagulation indication, atrial fibrillation 94.1 94.1
Medical history of heart failure 22.3 22.3
Medical history of diabetes 11.6 11.6
Medical history of myocardial infarction 10.7 10.7
Medical history of stroke 17.3 17.3
Concomitant use of an antiplatelet 22.7 22.7
Intracranial hemorrhage characteristics
Initial image to reversal start (hours), mean ± SD 2.4 ± 1.9 2.4 ± 2.7
End of reversal to repeat image (hours), mean ± SD 12.1 ± 1.2 12.1 ± 5.0
Traumatic onset, % 30.8 30.8
Infratentorial location, % 23.3 23.3
Initial intracerebral and/or intraventricular volume (mL), mean ± SD 7.3 ± 9.8 7.3 ± 9.1
Reversal agent dosing, %b
Andexanet alfa
 400 mg bolus + 440 mg infusion 95.2
 800 mg bolus + 860 mg infusion 4.8
4F-PCC
 25 units/kg infusion 86.1
 50 units/kg infusion 13.9

4F-PCC = four-factor prothrombin complex concentrate, GCS = Glasgow Coma Scale, SD = standard deviation

aBlood pressure reported was an average of the measurement at arrival and measurement just before reversal was administered

bNot included in propensity score